Publish time: 2023-10-12 00:00:00
28A-1100310
patent pending
Mesothelin (MSLN) is known to be expressed in the cell membrane of many epithelial malignancies. Antibody-drug conjugates (ADCs) targeting MSLN have been demonstrated to be a viable strategy in treating MSLN-positive cancers. We have used phage-display platform to find four anti-MSLN antibodies, which perform good binding ability to MSLN and chose them to develop ADCs for cancer treatment. Our animal experiment showed that these ADC candidates possess good even better efficacy of killing tumor cells than positive treatment control.
These ADCs perform excellent ability for treatment of MSLN-positive cancer cell.
These ADC products can be authorized to drug companies for development of cancer treatment.
An-Suei, Yang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Treating mesothelin-positive human gastric and pancreatic tumor in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries